Locally Advanced Rectal Adenocarcinoma
12
3
5
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.3%
1 terminated out of 12 trials
66.7%
-19.8% vs benchmark
8%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
ctDNA-Informed Management of Early-Stage Rectal Cancer
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma